Deals: Page
-
Permission granted by Gilead Sciences
Gilead to buy cancer drugmaker Immunomedics for $21B
The acquisition capped an active year of dealmaking for Gilead, which under CEO Daniel O'Day aims to become as well known for its cancer drugs as its HIV and hepatitis C medicines.
By Ned Pagliarulo • Updated Sept. 14, 2020 -
AbbVie wagers up to $2B on a Chinese biotech's cancer drug
The licensing deal hands AbbVie exclusive rights to a drug targeting CD47, a protein that has caught the attention of drugmakers like Gilead and Celgene.
By Jacob Bell • Sept. 4, 2020 -
Permission granted by Gilead Sciences
Gilead deal reignites optimism in a cancer biotech
A year after Jounce Therapeutics and Celgene ended a wide-ranging alliance, Gilead has teamed up with the Massachusetts biotech.
By Jacob Bell • Sept. 1, 2020 -
Ionis, changing its strategy, reels its spinoff back in
Reversing course on plans to rely on others to sell its drugs, the biotech will spend about half a billion dollars to acquire its own spinoff, Akcea.
By Jacob Bell • Aug. 31, 2020 -
Nestlé buys the rest of Aimmune, aiming to boost a struggling peanut allergy treatment
The Swiss firm will take over the launch of Aimmune's Palforzia, sales of which have disappointed since its approval in January.
By Ben Fidler • Aug. 31, 2020 -
Proteostasis bows out of cystic fibrosis drugmaking through Yumanity merger
The biotech's plans to challenge Vertex Pharmaceuticals have fallen short, leading to a merger with a neuroscience-focused startup.
By Jacob Bell • Aug. 24, 2020 -
Momenta shift to new drugs pays off with $6.5B buyout by J&J
Once a leader in biosimilar development, Momenta pivoted toward developing treatments for autoimmune diseases, including one that drew J&J's interest.
By Jonathan Gardner • Aug. 19, 2020 -
Courtesy of Eli Lilly
Lilly doubles down on Innovent cancer drug in immunotherapy push
The Indianapolis pharma paid $200 million to gain most of the rights to Tyvyt, a checkpoint blocker that could help it compete with Merck, Roche and others.
By Ben Fidler • Aug. 18, 2020 -
Permission granted by Gilead Sciences
Gilead expands Tango alliance, continuing a busy year of cancer deals
A $145 million payment to broaden a partnership with Tango Therapeutics is the latest in a series of deals Gilead has made to grow its oncology business.
By Jonathan Gardner • Aug. 18, 2020 -
Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly
For $475 million in near-term cash, Bristol Myers will get access to an immunotherapy based on technology that's drawn interest from rival Merck.
By Ben Fidler • Aug. 17, 2020 -
Courtesy of Sanofi
Sanofi, seeking control of key drug, to buy Principia for $3.7B
The acquisition significantly increases Sanofi's bet on Principia's chief asset, an experimental drug for multiple sclerosis now in late-stage testing.
By Ned Pagliarulo • Aug. 17, 2020 -
CureVac grabs $213M in US IPO, adding to year's record pace
Biotechs have raised nearly $10 billion from 45 initial public offerings this year, with CureVac's fueling the development of a coronavirus vaccine.
By Ben Fidler • Aug. 14, 2020 -
Bayer, contrasting pharma peers, builds up women's health business with $425M deal
Acquiring KaNDy Therapeutics hands Bayer an experimental menopause drug that, according to the company, could become a blockbuster product.
By Jacob Bell • Aug. 11, 2020 -
A hedge fund bets on a biotech startup to bring new drugs to China
The unusual startup already has partial rights to multiple drugs developed by MyoKardia and affiliates of BridgeBio, and plans to acquire many more.
By Ben Fidler • Aug. 11, 2020 -
Biogen makes a billion-dollar bet on Parkinson's drugs
In one of its biggest deals to date, Biogen plans to take an equity stake in Denali Therapeutics to gain access to new treatments for Parkinson's disease.
By Jacob Bell • Aug. 6, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
US to pay $1B to stock up on J&J's coronavirus vaccine
The agreement, which would supply the U.S. with 100 million doses of J&J's experimental shot, is the latest in a string of deals the country has reached with vaccine developers.
By Kristin Jensen • Aug. 5, 2020 -
Getty / Edited by BioPharma Dive
Sangamo, Novartis team up to develop genetic medicines for autism, other brain disorders
The deal, which hands Sangamo $75 million upfront, is the second pharma partnership the biotech has signed this year to focus on brain disease drugs.
By Kristin Jensen • July 30, 2020 -
AstraZeneca turns again to Daiichi Sankyo for a major cancer drug deal
The British pharma will pay Daiichi $1 billion to split rights to an experimental antibody-drug conjugate in a deal similar to the 2019 agreement that bought it the breast cancer drug Enhertu.
By Ned Pagliarulo • July 27, 2020 -
Moderna, pacing a global vaccine race, loses a key patent fight
A patent board ruled that Arbutus Biopharma invented a technology Moderna uses to deliver its vaccines, which may have implications for its industry-leading coronavirus shot.
By Jonathan Gardner • July 24, 2020 -
EQRx, gearing up for a price war with big pharma, buys two cancer drugs
The unusual startup aims to speed potential rivals to blockbuster medicines Ibrance and Tagrisso to market and price them at a "small fraction" of the cost, CEO Alexis Borisy told BioPharma Dive.
By Ben Fidler • July 23, 2020 -
Permission granted by Gilead Sciences
Gilead adds to string of cancer drug deals with Tizona stake
An upfront payment of $300 million gives Gilead a nearly 50% stake in Tizona Therapeutics and the exclusive option to acquire it later, depending on how promising the biotech's immunotherapy looks.
By Jacob Bell • July 21, 2020 -
GSK invests in mRNA vaccines through deal with CureVac
While CureVac's coronavirus work is excluded from the deal, GSK said the biotech's platform should complement its existing vaccine technology and provide greater access to manufacturing.
By Jacob Bell • July 20, 2020 -
Sanofi, on the lookout for acquisitions, may have spotted a target
A Bloomberg report names Principia Biopharma, a biotech with an existing partnership with Sanofi, among the U.S. companies that the French pharma is evaluating for possible deals.
By Jacob Bell • July 17, 2020 -
Permission granted by Roche
Blueprint, eyeing an independent future, gets $775M in new Roche alliance
The deal, which gives Roche rights to Blueprint's lead drug pralsetinib, is another bet by the Swiss drugmaker on targeted cancer therapies.
By Ben Fidler • Updated July 14, 2020 -
Blackstone caps off private equity's largest-ever life sciences fund
At $4.6 billion, the fund signals that one of the most powerful groups in private equity sees strong demand for biotech investment.
By Jacob Bell • July 10, 2020
Previous
